Molecular and Cellular Characterization of Prognostic Immune Response in Childhoo

儿童预后免疫反应的分子和细胞特征

• 批准号: 8206723
• 负责人: NICHOLAS K FOREMAN
• 金额: $ 30.8万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-17 至 2013-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8206723
• 关键词: Address; Animal Model; Bioinformatics; Biological; Biometry; Brain Neoplasms; Cells; Central Nervous System Neoplasms; Cessation of life; Child; Childhood; Childhood Brain Neoplasm; Childhood Ependymoma; Children' s Oncology Group; Clinic; Clinical; Clinical Management; Clinical Trials; Collaborations; Collection; Data; Development; Diagnosis; Dimensions; Dissection; Ensure; Ependymoma; Excision; Freezing; Frequencies; Future; Gene Expression; Gene Expression Microarray Analysis; Genes; Goals; Histology; Human; Immune; Immune response; Immune system; Immunotherapeutic agent; Immunotherapy; Investigational Therapies; Knowledge; Laboratories; Little' s Disease; Location; Malignant Neoplasms; Measures; Molecular; Nervous System Trauma; Neuraxis; Operative Surgical Procedures; Outcome; Paraffin Embedding; Patient Selection; Patients; Peripheral; Phenotype; Population; Positioning Attribute; Prognostic Factor; Prognostic Marker; Prospective Studies; Proteins; Proteomics; Radiation therapy; Recurrence; Research; Research Personnel; Research Proposals; Residual Tumors; Retrospective Studies; Role; Sample Size; Sampling; Screening procedure; Series; Severity of illness; Specimen; Testing; Tissue Sample; Tissues; Translating; Two-Dimensional Gel Electrophoresis; Validation; base; design; effective therapy; immune function; improved; neoplastic cell; neuro-oncology; overexpression; peripheral blood; prognostic; prospective; protein expression; public health relevance; response; success; tumor; tumor immunology

DESCRIPTION (provided by applicant): Ependymoma (EPN), the third most common brain tumor of pediatrics, is treated by surgical removal and radiation therapy. Unfortunately, more than 50% of children with EPN will suffer from tumor recurrence, which will ultimately result in death. Despite the severity of this disease, little progress has been made in identification of factors underlying EPN recurrence. The long-term goal of my research addresses this urgent need by searching more effective prognostic markers for EPN and elucidating EPN biological information that could facilitate development of more effective therapies. Recent microarray gene expression studies by my laboratory revealed that the predominant feature that distinguishes EPN from children whose tumor did not recur versus those whose did is an overexpression of immune response related genes. These results suggest that a host anti-tumor immune response in EPN, when combined with standard therapy, results in complete eradication of the remaining residual tumor cells. My central hypothesis is that detailed characterization of the immune related genes associated with good clinical outcome in EPN will simultaneously (a) provide an accurate prognostic marker for EPN, and (b) provide critical knowledge of the interaction between the human immune system and CNS tumors that will aid our understanding of host tumor control. Progress on either of these fronts would benefit clinical trials in childhood EPN. The specific aims of my research proposal are (i) retrospective global gene and protein expression analysis of frozen tumor specimens, (ii) retrospective histological analysis of candidate immune cells and molecules in paraffin embedded and frozen tumor, and (iii) prospective analysis of tumor-infiltrating and peripheral immune cells using fresh surgical samples. The results of these studies will potentially solve the clinical problem of how to identify those children with EPN who will recur, which will allow us to better focus patient selection for clinical trials. In addition to this, and with a wider importance to immunotherapy of tumors in the CNS and elsewhere, is the characterization of the putative host anti-tumor immune response that we have identified in good outcome associated EPN. Previous CNS tumor immunotherapeutic strategies, largely based on the results of animal models, have shown limited success. The proposed research may overcome this barrier by advancing our overall understanding of how the body naturally initiates and effects an immune response against CNS tumors in humans, rather than the approximation of this previously afforded by such animal models. This knowledge could then be used to improve therapy for those children with a likelihood of EPN recurrence, with potential application in other CNS malignancies. PUBLIC HEALTH RELEVANCE: Most people with brain tumors die. We have found an immune response in a type of childhood brain tumor called an ependymoma. We wish to explore whether this immune response can be used to cure ependymomas and potentially other brain tumors.

描述（由申请人提供）：第三个最常见的儿科脑肿瘤（EPN）通过手术切除和放射疗法治疗。不幸的是，超过50％的EPN儿童将患有肿瘤复发，最终会导致死亡。尽管这种疾病严重程度，但在确定EPN复发的因素方面几乎没有取得进展。我的研究的长期目标通过搜索更有效的预后标记来解决EPN和阐明EPN生物学信息，从而促进更有效的疗法的开发，从而解决了这一迫切需求。我的实验室最近的微阵列基因表达研究表明，将EPN与肿瘤没有复发的儿童与那些对免疫反应相关基因过表达的儿童区分开的主要特征。这些结果表明，EPN中的宿主抗肿瘤免疫反应与标准疗法结合使用，导致剩余的残留肿瘤细胞完全消除。我的中心假设是，与EPN中与良好临床结果相关的免疫相关基因的详细表征（a）将为EPN提供准确的预后标志物，（b）提供了有关人类免疫系统与CNS肿瘤之间相互作用的关键知识，这将有助于我们对宿主肿瘤控制的理解。这两个方面的进展都将使儿童期EPN的临床试验受益。我的研究提案的具体目的是（i）回顾性全球基因和蛋白质表达分析，对冷冻肿瘤标本的蛋白质表达分析，（ii）嵌入和冷冻肿瘤中的候选免疫细胞和分子的回顾性组织学分析，以及（iii）使用肿瘤中的肿瘤和per骨免疫细胞的前瞻性分析。这些研究的结果将有可能解决如何识别那些将复发的EPN儿童的临床问题，这将使我们能够更好地将患者选择临床试验。除此之外，对于中枢神经系统和其他地方的肿瘤的免疫疗法而言，这是我们在良好结局相关的EPN中确定的推定宿主抗肿瘤免疫反应的表征。以前的中枢神经系统肿瘤免疫治疗策略主要基于动物模型的结果，已经显示出有限的成功。提出的研究可能通过促进我们对人体自然启动和影响人类中枢神经系统肿瘤的免疫反应的整体理解来克服这一障碍，而不是对这种动物模型先前提供的近似。然后，这些知识可用于改善具有EPN复发可能性的儿童的治疗，并可能在其他中枢神经系统恶性肿瘤中应用。 公共卫生相关性：大多数患有脑肿瘤的人死亡。我们发现在一种称为室温室瘤的儿童脑肿瘤中存在免疫反应。我们希望探索这种免疫反应是否可以用于治愈室心膜瘤和可能其他脑肿瘤。